Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Explore this paper's citation graph
Summary
Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.
- Type
- article
- Published
- 2014-05-14
- Cited by
- 1,822
- References
- 18
- Access
- Open access
- OpenAlex
- https://openalex.org/W2092646281
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23322412
Keywords
Ledipasvir, Sofosbuvir, Medicine, Ribavirin, Internal medicine
References
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
- Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
- Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
- Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
- A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.
- Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
- Direct Acting Antiviral Agents and the Path to Interferon Independence
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
- Telaprevir for previously untreated chronic hepatitis C virus infection.
- Telaprevir for retreatment of HCV infection.
- Efficacy of Sofosbuvir and Ribavirin for treatment of Hepatitis C Genotype-1 in an Inner City Population: Virus and Host Factors that Predict Relapse
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
- Interpretation:An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases
Cited by
- Arbeitsbedingte Blutexpositionen in der Polytraumaversorgung
- Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy
- Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
- Therapie der Hepatitis C
- Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
- Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis
- C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients.
- Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
- Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
- Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients
- Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
- Impact of anti‐HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid‐term follow‐up in a single‐center cohort study
- Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
- Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
- Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
- Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals
- Risikoeinschätzung von blutübertragbaren Infektionen durch die Schockraummitarbeiter
- Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections
- Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C
- Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy
Related papers
- Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)
- Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients
- TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 6 PATIENT WITH TRIPLE THERAPY PEG-IFN, RIBAVIRIN AND SOFOSBUVIR: CASE REPORT AND REVIEW OF LITERATURE
- Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment
- 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin
- Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment‐experienced individual
- Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
- PE-074 : Efficacy and Safety of Sofosbuvir and Ribavirin in Treatment of HCV Genotype 2
- Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
- Safety and Efficacy of Ledipasvir/Sofosbuvir on Hepatitis C Eradication in HCV/ HIV Co-infected Patients: 2771